The two most common forms of breast cancer are invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), named for where in the breast they originate. Ductal carcinoma starts in the cells lining the milk ducts; lobular carcinoma starts in the lobules, the small glands that actually produce milk. Ductal is far more common, but the lobular type has been rising steadily for decades and behaves differently enough that it affects screening, surgery, treatment choices, and long-term outlook in ways many patients and even some clinicians underestimate.
How Common Is Each Type
Ductal carcinoma accounts for roughly 70 to 80 percent of all invasive breast cancers. Lobular carcinoma is the second most common, making up about 10 to 15 percent of diagnoses. In 2021, the incidence of ILC was around 14 per 100,000 women, representing about one in ten breast cancer cases.1PubMed Central. Lobular breast cancer statistics, 2025 Those proportions have shifted over time. Between 1987 and 1999, ductal carcinoma rates stayed essentially flat while lobular rates climbed roughly 50 percent, and the share of breast cancers with a lobular component rose from about 9.5 percent to nearly 16 percent.2PubMed. Trends in incidence rates of invasive lobular and ductal breast carcinoma That upward trend has continued into recent years across all racial and ethnic groups.1PubMed Central. Lobular breast cancer statistics, 2025
Part of the historical increase is probably better pathology classification, but researchers have also pointed to widespread use of combination hormone replacement therapy (HRT) during the 1990s, since lobular cancers are overwhelmingly hormone-receptor positive. The remaining subtypes beyond ductal and lobular, including tubular, mucinous, medullary, and papillary carcinomas, are individually uncommon, each accounting for just a few percent or less of cases. Practically speaking, when someone is diagnosed with breast cancer, the first distinction a pathologist draws is ductal versus lobular.
What Makes Them Look Different Under the Microscope
The two types grow in fundamentally different architectural patterns. Ductal carcinoma cells tend to cluster together, forming visible masses, irregular sheets, or gland-like structures. They push outward as a cohesive clump, which is part of why they often show up as a distinct lump on imaging or physical exam.
Lobular carcinoma cells do the opposite. They infiltrate the surrounding tissue in thin, single-file lines, sometimes wrapping in concentric rings around normal ducts in what pathologists call a “targetoid” pattern.3PubMed Central. “Single file” pattern in histopathology Instead of forming a hard lump, lobular cancer spreads like fingers through the breast tissue, which makes it sneaky. Patients sometimes describe a vague thickening rather than a discrete mass, and on mammography, the tumor can blend in with normal breast tissue instead of forming a bright, obvious spot.
The Genetic Key Behind the Difference
The single-file growth pattern of lobular cancer traces back to one molecular event: loss of E-cadherin, a protein that acts like glue between cells. E-cadherin is encoded by a gene called CDH1, and in lobular breast cancer, CDH1 is almost always inactivated through mutations, deletions, or chemical silencing of the gene’s promoter. Without E-cadherin holding cells together, lobular cancer cells lose their adhesion to one another and slip through surrounding tissue individually.4PubMed Central. The Role of the CDH1 Gene in the Pathogenesis and Progression of Lobular Breast Cancer
This is the defining molecular distinction between the two types. Ductal carcinomas almost always retain E-cadherin, which is why pathologists use an E-cadherin stain as a quick test when a tumor’s identity is unclear: if the cells stain positive, it looks ductal; if they don’t, it looks lobular. A small subset of lobular cancers lack obvious CDH1 mutations but still lose E-cadherin through promoter methylation or through mutations in other adhesion genes such as CTNND1 or AXIN2.5npj precision oncology. Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations Regardless of which gene is disrupted, the outcome converges on the same thing: cells that can no longer stick together.
Hormone Receptors and Molecular Profiles
Lobular cancers are overwhelmingly hormone receptor positive. They express estrogen receptors (ER) and progesterone receptors (PR) at higher rates than ductal cancers, and they are almost always HER2 negative.6Scientific Reports. Invasive ductal and lobular carcinoma and receptor status in the genetic context of breast cancer They also tend to be lower grade, meaning their cells look more like normal breast cells and divide more slowly.7PLOS ONE. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma On paper, this sounds like good news, and in some ways it is. But that favorable hormone-receptor profile can be misleading when it comes to predicting how lobular cancer will respond to treatment over the long haul.
Ductal cancers span a wider molecular spectrum. Some are hormone receptor positive and relatively slow-growing. Others are HER2 positive, which once carried a grim prognosis but now responds well to targeted HER2-blocking drugs. A significant fraction of ductal cancers are triple-negative, meaning they lack estrogen, progesterone, and HER2 receptors, leaving chemotherapy as the primary weapon. Lobular cancers almost never fall into the triple-negative category, so the most aggressive molecular subtypes are effectively a ductal problem.
Why Lobular Cancer Is Harder to Find on Imaging
Because lobular tumors infiltrate diffusely rather than forming a dense mass, they are often underestimated or missed entirely on standard mammography. They may not produce the classic bright spot or architectural distortion that radiologists are trained to flag. This is not a minor detection gap. Conventional imaging (mammography plus ultrasound) underestimates the size of lobular tumors far more often than it does ductal tumors.
MRI is substantially better at measuring lobular cancer. One study of 56 women found that conventional imaging underestimated the span of ILC over 40 percent of the time, compared to 18 percent of the time with MRI, and the overall agreement with the final pathology size was significantly closer for MRI.8PubMed Central. Accuracy of Preoperative Breast MRI Versus Conventional Imaging in Measuring Pathologic Extent of Invasive Lobular Carcinoma A separate prospective and retrospective analysis found that MRI’s correlation with final tumor size was 0.88, compared to 0.57 for ultrasound and 0.40 for mammography.9PubMed. Value of MRI in the surgical planning of invasive lobular breast carcinoma That same study reported MRI’s sensitivity for detecting the tumor at 100 percent, with a specificity of 87 percent. For this reason, many breast centers now recommend MRI as part of the preoperative workup when a lobular diagnosis is suspected.
Even MRI is imperfect, though. After neoadjuvant (pre-surgery) treatment, MRI still underestimated residual lobular tumor size in over half of cases, with an average underestimation of more than 3 centimeters when certain diffuse enhancement patterns were present.10PubMed Central. Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma This is one of the ways that lobular cancer’s infiltrative habit creates downstream surgical challenges.
Surgical Challenges and Positive Margins
When you try to remove a tumor that doesn’t form a neat ball, the surgeon is essentially trying to excise something whose borders are blurry. The result: lobular cancers have significantly higher rates of positive surgical margins after breast-conserving surgery (lumpectomy), meaning cancer cells are found at the edge of the removed tissue. One study found positive margins in 45 percent of ILC cases versus about 17.5 percent of IDC cases, leading to re-excision surgery more than half the time for lobular patients.11PubMed. Invasive lobular carcinoma of the breast: local recurrence after breast-conserving therapy by subtype approximation and surgical margin In another cohort, positive margins occurred in about 38 percent of lobular cases treated with breast-conserving surgery, and among those who underwent re-excision lumpectomy, roughly a quarter still came back with positive margins, ultimately requiring mastectomy.12npj Breast Cancer. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast
A recent meta-analysis found that lobular patients undergoing oncoplastic breast-conserving surgery (which uses plastic surgery techniques to reshape the breast while removing more tissue) had a positive margin rate of about 31 percent, with a risk more than three times higher than ductal patients undergoing the same procedure. However, for larger lobular tumors, oncoplastic techniques actually cut the positive margin risk roughly in half compared to standard lumpectomy.13PubMed Central. Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery Because of these challenges, lobular patients are more likely to undergo mastectomy than ductal patients with comparable tumor sizes.7PLOS ONE. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma
Response to Chemotherapy
Lobular breast cancer responds poorly to chemotherapy compared to ductal cancer. In a large meta-analysis of neoadjuvant (pre-surgery) chemotherapy trials, ductal cancers achieved a complete pathologic response, meaning no detectable cancer remaining, about 22 percent of the time, while lobular cancers achieved it in only about 7 percent of cases.14PubMed Central. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis Some published series report complete response rates for lobular cancer as low as 1 to 6 percent.15The ASCO Post. Lobular vs Ductal Breast Cancer: Distinctions in Management
This matters in practical terms. Neoadjuvant chemotherapy is sometimes used to shrink a large tumor before surgery, making breast conservation possible. For ductal cancers, the approach often works well enough to downstage the tumor. For lobular cancers, the tumor frequently does not shrink meaningfully, and patients end up needing mastectomy regardless. This is why oncologists treating lobular cancer sometimes weigh the limited benefit of neoadjuvant chemo against going directly to surgery.
Endocrine Therapy Makes a Bigger Difference in Lobular Cancer
Given how strongly lobular cancers express hormone receptors, it makes sense that anti-estrogen treatments are the backbone of lobular cancer therapy. And here, the news is more encouraging. Data from the large BIG 1-98 trial showed that lobular cancer patients benefited substantially more from the aromatase inhibitor letrozole than from the older drug tamoxifen. In the lobular subset, letrozole reduced the risk of recurrence by 50 to 66 percent compared to tamoxifen, depending on the molecular subtype. By contrast, the advantage of letrozole over tamoxifen was smaller and sometimes absent in ductal cancers.16PubMed Central. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Similarly, another trial comparing two aromatase inhibitors (anastrozole and exemestane) found a suggestive survival advantage favoring anastrozole specifically in the lobular subgroup, with no such difference in the ductal group.17PubMed. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 The clinical takeaway is that the choice of endocrine drug may matter more for lobular patients than for ductal patients, and aromatase inhibitors appear to outperform tamoxifen more decisively in lobular disease.
Where Each Type Tends to Spread
When breast cancer metastasizes, the two types show strikingly different preferences for where they go. Ductal carcinoma most commonly spreads to the lungs, liver, and bones. Lobular carcinoma is far less likely to spread to the lungs but far more likely to show up in unusual locations: the peritoneum (the lining of the abdominal cavity), the gastrointestinal tract, the retroperitoneum, and even the ovaries.18PubMed Central. Infiltrative pattern of metastatic invasive lobular breast carcinoma in the abdomen: a pictorial review
One retrospective study quantified the difference dramatically: lung metastases were found in only about 6 percent of metastatic lobular cases versus nearly 54 percent of metastatic ductal cases, while peritoneal metastases occurred in roughly 69 percent of lobular cases compared to just 1 percent of ductal cases.19PubMed. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer These abdominal metastases can be subtle and infiltrative, much like the primary tumor, and they sometimes mimic other conditions like ovarian cancer or irritable bowel symptoms. Knowing that a patient’s original cancer was lobular can help clinicians look in the right places if new symptoms arise years later.
The Late Recurrence Problem
Perhaps the most important prognostic difference between ductal and lobular cancer is the timing of recurrence. In the first five to ten years after diagnosis, lobular cancer actually has a better or comparable survival to ductal cancer. But after ten years, the pattern reverses. A large multi-database study of premenopausal patients found that lobular cancers had better breast cancer-specific survival than ductal in the first decade, but the hazard roughly doubled after year ten.20JAMA Network Open. Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma
A separate analysis of clinical trial data showed this late divergence clearly: the five-year disease-free survival for ER-positive lobular and ductal cancers was identical at 94 percent, but by 20 years, lobular disease-free survival had fallen to 72 percent versus 83 percent for ductal. Overall survival was also worse for lobular patients.21JNCI: Journal of the National Cancer Institute. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer The pattern of annual hazard is different, too: ductal recurrence events tend to peak around year five and then decline, while lobular events peak around year five and then remain at a steady elevated level for years afterward. This means that lobular cancer patients need longer and more vigilant follow-up, and it raises the question of whether extended endocrine therapy beyond the standard five or ten years could close that gap.
In Situ Stages and What They Mean
Both ductal and lobular cancers have in situ counterparts, confined to the ducts or lobules and not yet invasive. Ductal carcinoma in situ (DCIS) is widely understood as a direct precursor to invasive ductal cancer. Lobular carcinoma in situ (LCIS) is more ambiguous: it’s considered a risk factor for developing invasive cancer, but whether it’s truly a precursor that will inevitably progress is less clear.22PubMed Central. DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?
A study of women diagnosed with either DCIS or LCIS found that LCIS patients were more than five times as likely as DCIS patients to eventually develop invasive lobular cancer specifically. LCIS patients also had somewhat higher overall rates of subsequent invasive breast cancer in both the same and the opposite breast.23PubMed. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001 DCIS is typically treated aggressively, often with surgery and sometimes radiation. LCIS, by contrast, is more often managed with close surveillance and risk-reducing medication, though practice varies and this remains an evolving area.
Contralateral Risk
A common concern after a breast cancer diagnosis is whether the other breast is at heightened risk. One large registry study found no significant overall difference in contralateral cancer rates between ductal and lobular patients, at roughly 3 percent for both.24PubMed. Contralateral breast cancer: incidence according to ductal or lobular phenotype of the primary However, when researchers looked specifically at cancers detected within six months of the original diagnosis (essentially synchronous cancers), lobular patients had a modestly but significantly higher rate, consistent with the idea that a diffuse lobular tumor in one breast may signal the need for closer imaging of the other.25PubMed Central. Contralateral breast cancer risk in relation to tumor morphology and age-in which patients is preoperative MRI justified? This is one reason some centers advocate for bilateral breast MRI in patients newly diagnosed with ILC.
Lobular Cancer in Men
Male breast cancer accounts for about 1 percent of all breast cancers and is overwhelmingly ductal. Lobular breast cancer in men is extremely rare, and the likely explanation is straightforward: the male breast has very little lobular development, so there is barely any lobular tissue in which this cancer could originate.26PubMed Central. Invasive lobular carcinoma of the male breast – a systematic review with an illustrative case study When male lobular cancer does occur, it has been associated with conditions that promote lobular growth, including Klinefelter syndrome and exogenous estrogen exposure.
Racial and Ethnic Patterns
Lobular breast cancer shows notable demographic variation. White women have the highest incidence at about 14.7 per 100,000, while rates in Black, Hispanic, and Asian American/Pacific Islander women are roughly a third to half as high. This stands in contrast to ductal cancer, where Black women have the highest incidence before age 40, partly driven by higher rates of triple-negative disease.1PubMed Central. Lobular breast cancer statistics, 2025 The reasons for this disparity are not fully understood but likely involve a combination of hormonal exposures, genetic factors, and differences in body composition.
Emerging Treatments Targeting Lobular Biology
Because lobular cancer’s resistance to chemotherapy and its late-recurrence problem leave real clinical gaps, researchers are looking for treatments that exploit its specific molecular weaknesses. One of the more intriguing leads involves a concept called synthetic lethality: because lobular cancer cells have already lost E-cadherin, they become dependent on other survival pathways. One such pathway involves a protein called ROS1. A phase II clinical trial called ROLO is testing whether a ROS1 inhibitor (crizotinib, originally developed for certain lung cancers) can exploit this dependency in advanced E-cadherin-negative, ER-positive lobular breast cancer.27The Oncologist. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer Laboratory studies have shown that E-cadherin-defective cells rely on ROS1, and blocking it triggers cell death, a vulnerability that ductal cancer cells, with their intact E-cadherin, would not share. If trials like ROLO succeed, they could open the door to the first truly lobular-specific targeted therapies.